Article
5m Read
January 07, 2026
TECH AND DISEASE TRENDS
prod:prod_dcx-login
The Need
The Philadelphia (Ph) chromosome is observed in patients with chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML).1
Guidelines recommend periodic monitoring of BCR::ABL 190 transcript as a significant predictor of relapse in Ph+ ALL and CML patients.2-4
Lack of international standard methods make comparison of BCR::ABL p190 quantification from laboratory-to-laboratory challenging.
Guidelines recommend periodic monitoring of BCR::ABL 190 transcript as a significant predictor of relapse in Ph+ ALL and CML patients.2-4
Lack of international standard methods make comparison of BCR::ABL p190 quantification from laboratory-to-laboratory challenging.
1 Reckel, S., Hamelin, R., Georgeon, S. et al. Differential signaling networks of Bcr–Abl p210 and p190 kinases in leukemia cells defined by functional proteomics. Leukemia 31,
1502–1512 (2017)
2 NCCN Guidelines for Patients Acute Lymphoblastic Leukemia, 2021
3 ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up of Acute Lymphoblastic Leukaemia
4 Canadian Cancer Society Follow-up after treatment for acute lymphocytic leukemia.
1502–1512 (2017)
2 NCCN Guidelines for Patients Acute Lymphoblastic Leukemia, 2021
3 ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up of Acute Lymphoblastic Leukaemia
4 Canadian Cancer Society Follow-up after treatment for acute lymphocytic leukemia.
The Solution
The Xpert® BCR-ABL Ultra p190 is an automated test for quantifying the amount of BCR::ABL1 p190 transcript as a ratio of BCR::ABL p190/ABL1 with high sensitivity.7
Proprietary in-house RNA control materials are used to calibrate and standardize and align indirectly with the WHO IS (NIBSC-09/138) for BCR::ABL p210.6,7
6 Yuanyuan Liu, Tran Tran, Phat Nguyen, Huilin Wei, Gwo-Jen Day, Lin Yuan; Development of Reference Control Material for the Evaluation of the Cepheid Prototype * Xpert®
BCR-ABL P190 Ultra Assay. Blood 2019; 134 (Supplement_1): 5213
7 Xpert BCR-ABL Ultra Instructions for Use
BCR-ABL P190 Ultra Assay. Blood 2019; 134 (Supplement_1): 5213
7 Xpert BCR-ABL Ultra Instructions for Use
The Impact
- Monitor treatment response and Minimum Residual Disease (MRD) for Ph-positive (Ph+) ALL and CML patients.8
- Timely monitoring ensures the identification of high-risk patients associated with an inferior outcome to therapy.5
- Optimize lab organization with standardized reporting.6
5 Gandhe N, Vekaria M, Dabak V. A Rare Case of p190 BCR-ABL Chronic Myeloid Leukemia With a Very Good Response to Tyrosine Kinase Inhibitors. Cureus. 2021 Aug
5;13(8):e16914. doi: 10.7759/cureus.16914. PMID: 34513487; PMCID: PMC8418323.
6 Yuanyuan Liu, Tran Tran, Phat Nguyen, Huilin Wei, Gwo-Jen Day, Lin Yuan; Development of Reference Control Material for the Evaluation of the Cepheid Prototype * Xpert®
BCR-ABL P190 Ultra Assay. Blood 2019; 134 (Supplement_1): 5213
8 Soverini S, Bassan R, Lion T. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol.
2019 Apr 23;12(1):39. doi: 10.1186/s13045-019-0729-2. PMID: 31014376; PMCID: PMC6480772.
5;13(8):e16914. doi: 10.7759/cureus.16914. PMID: 34513487; PMCID: PMC8418323.
6 Yuanyuan Liu, Tran Tran, Phat Nguyen, Huilin Wei, Gwo-Jen Day, Lin Yuan; Development of Reference Control Material for the Evaluation of the Cepheid Prototype * Xpert®
BCR-ABL P190 Ultra Assay. Blood 2019; 134 (Supplement_1): 5213
8 Soverini S, Bassan R, Lion T. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol.
2019 Apr 23;12(1):39. doi: 10.1186/s13045-019-0729-2. PMID: 31014376; PMCID: PMC6480772.
Insights
Video
5m Watch
October 09, 2025
TECH AND DISEASE TRENDS